190 related articles for article (PubMed ID: 1184969)
1. Preparation and properties of an antiplasma cell serum directed against a defined plasmacytoma cell population.
Proctor ML; Herscowitz HB
J Immunol; 1975 Dec; 115(6):1642-9. PubMed ID: 1184969
[TBL] [Abstract][Full Text] [Related]
2. Rabbit anti-EL4 serum. A reagent with specificity for a population of murine suppressor cells.
Al-Sakkaf L; Cooke A; Hutchings P; Jones B
Immunology; 1979 Oct; 38(2):375-83. PubMed ID: 159864
[TBL] [Abstract][Full Text] [Related]
3. The expression on mouse lymphoid cells of Th-B, an antigen common to mouse B cells and thymus cells.
Yutoku M; Grossberg AL; Pressman D
J Immunol; 1975 Jul; 115(1):69-74. PubMed ID: 1097506
[TBL] [Abstract][Full Text] [Related]
4. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
5. Generation of anti-MOPC-315 cytotoxicity in uneducated or in vitro educated spleen cells from normal or MOPC-315 tumor-bearing mice pretreated in vivo with Bacillus Calmette-Guérin.
Braun DP; Mokyr MB; Dray S
Cancer Res; 1978 Jun; 38(6):1626-32. PubMed ID: 647676
[TBL] [Abstract][Full Text] [Related]
6. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. I. Analysis of immune parameters involved.
Cihak J; Ziegler HW; Kölsch E
Immunology; 1981 May; 43(1):133-43. PubMed ID: 6265346
[TBL] [Abstract][Full Text] [Related]
7. Xenoantisera against a murine T cell tumor product cross-react with immunoglobulin Fab determinants.
Mackel AM; Craddock GR; Warr GW; DeLuca D; Marchalonis JJ
J Immunol; 1983 Sep; 131(3):1582-90. PubMed ID: 6350458
[TBL] [Abstract][Full Text] [Related]
8. Regulation of immune responses aginst the syngeneic ADJ-PC-5 plasmacytoma in BALB-c mice. III. Induction of specific T suppressor cells to the BALB/c plasmacytoma ADJ-PC-5 during early stages of tumorigenesis.
Haubeck HD; Kölsch E
Immunology; 1982 Nov; 47(3):503-10. PubMed ID: 6215340
[TBL] [Abstract][Full Text] [Related]
9. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
Nio Y; Ohgaki K; Tobe T
J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
[TBL] [Abstract][Full Text] [Related]
10. Studies on the cytolytic attack mechanism of the cytotoxic T lymphocyte (CTL): preparation of antisera against cellfree cytosolic extracts of a CTL clone capable of blocking the lethal hit stage of CTL cytolysis and analysis of the cytolytic structure.
Hiserodt JC
J Immunol; 1985 Jul; 135(1):53-62. PubMed ID: 3158707
[TBL] [Abstract][Full Text] [Related]
11. Rabbit anti-EL4 serum. A reagent which discriminates between murine cytotoxic and suppressor cells.
Al-Sakkaf L; Cooke A; Heppel L; Hutchings P; Jones B
Immunology; 1979 Nov; 38(3):609-12. PubMed ID: 42615
[TBL] [Abstract][Full Text] [Related]
12. Continuous cytotoxic T cell lines reactive against murine plasmacytoma tumor-associated antigens.
Giorgi JV; Warner NL
J Immunol; 1981 Jan; 126(1):322-30. PubMed ID: 6161166
[TBL] [Abstract][Full Text] [Related]
13. The allogeneic effect on tumor growth. I. Inhibition of a murine plasmacytoma, MOPC 315, by the graft-vs-host reaction.
Osborne DP; Katz DH
J Immunol; 1977 Apr; 118(4):1441-8. PubMed ID: 15034
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of antitumor cytotoxicity of MOPC-315 tumor bearer spleen cells by depletion of dinitrophenol-adherent cells prior to in vitro immunization.
Mokyr MB; Hengst JC; Przepiorka D; Dray S
Cancer Res; 1979 Oct; 39(10):3928-34. PubMed ID: 157800
[No Abstract] [Full Text] [Related]
15. Augmentation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells by depletion of glass-adherent cells prior to in vitro activation.
Mokyr MB; Braun DP; Dray S
Cancer Res; 1979 Mar; 39(3):785-92. PubMed ID: 427766
[No Abstract] [Full Text] [Related]
16. Inhibition of growth of MOPC 104E cells in immunosuppressed mice.
Hiramoto RN; Cox PJ; Hiramoto NS; Ghanta VK
J Immunol; 1984 Dec; 133(6):3424-8. PubMed ID: 6386985
[TBL] [Abstract][Full Text] [Related]
17. Effect of subcutaneously administered 2,6,10,14-tetramethylpentadecane on plasmacytoma growth.
Platica M; Bojko C; Steiner G; Hollander VP
Cancer Res; 1980 Jul; 40(7):2229-33. PubMed ID: 6248200
[TBL] [Abstract][Full Text] [Related]
18. Release of immunosuppressive factor(s) by MOPC-315 murine plasmacytoma cells: a possible mechanism of defence.
Bomstein Y; Ophir R; Harshemes H; Ben-Efraim S
Anticancer Res; 1993; 13(6A):2125-9. PubMed ID: 8297124
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.
Mokyr MB; Bartik MM; Ahn MC
Cancer Res; 1989 Feb; 49(4):870-6. PubMed ID: 2783557
[TBL] [Abstract][Full Text] [Related]
20. Antibody in the sera of tumor-bearing mice that mediates spleen cell cytotoxicity toward the autologous tumor.
Blair PB; Lane MA; Mar P
J Immunol; 1976 Mar; 116(3):606-9. PubMed ID: 176266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
